EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 4

Ginkgo Ginkgo biloba L.

Also called: Ginkgo biloba, maidenhair tree, fossil tree

Ginkgo is a deciduous tree, the last remaining species of a primitive plant family, with a long history of use in Chinese medicine. Leaf extract is the most commonly used form today.

Category
Botanical
Part used
Leaf (usually as an extract)
Strongest evidence
C Limited
Reviewed
2026-10-28

Class 1 Well studied in people. A 2009 Cochrane review included 36 randomized, double-blind trials of Ginkgo biloba extract versus placebo in people with cognitive impairment or dementia; most tested the standardized extract EGb 761. [3]

Fact-checked 2026-10-28 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

5 topics studied2 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Ginkgo does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Ginkgo, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Dementia risk in older adultsXIn the GEM trial, more than 3,000 people aged 75 or older took ginkgo or placebo for a median of 6 years; dementia and Alzheimer's rates did not differ. [1]
Symptoms of dementia or cognitive impairmentCCochrane (2009): 36 trials, mostly small and under 3 months; results inconsistent, and authors found evidence of clinically significant benefit 'inconsistent and unreliable'. [3]
Cognitive performance in healthy peopleCNCCIH states it is uncertain whether ginkgo influences cognition in healthy people; much of the research is of low quality. [1]
Tinnitus, high blood pressure, heart disease, multiple sclerosisXNCCIH states research suggests ginkgo is not helpful for these. [1]
Anxiety, PMS, schizophrenia, vertigoCA small amount of evidence suggests benefit, but NCCIH calls the overall evidence not conclusive. [1]

Main constituents: Multiple compounds; ginkgolides and bilobalide are unique to this herb [2]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Typical oral dose is 120 to 240 mg per day, divided into 2 to 3 doses. [2]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Score E
    A: well known causeE: unlikely cause

    LiverTox likelihood score E: unlikely cause of clinically apparent liver injury (chapter last updated March 14, 2018).

    Details and sources
  • Pregnancy and breastfeeding
    EU monograph: well-established use is contraindicated in pregnancy …

    2 statements in the profile.

    Details and sources
  • Interactions with medicines
    7 listed

    Anticoagulants such as warfarin; Antiplatelet drugs and anticoagulants; Anticoagulant and antiplatelet treatment …

    Details and sources
  • Cancer evaluations (IARC, NTP)
    2 found

    Each names the exact material tested, which may differ from a supplement.

    Details and sources
  • FDA new dietary ingredient notifications
    1 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    EU herbal monograph on Ginkgo biloba L., folium (EMA/HMPC/321097/2012, 28 January 2015): well-established use, adults and elderly, dry extract (DER …

    Details and sources
  • Leaf extracts are likely safe for most adults in moderate oral amounts; used safely in studies lasting up to 6 years. [1]
  • Fresh ginkgo seeds are toxic when eaten; serious effects have also occurred with roasted seeds or the crude plant. [1]
  • Most common side effects: dizziness, gastrointestinal symptoms and headache. [1]
  • May be unsafe in pregnancy; might cause early labor or extra bleeding during delivery if used near that time. Little is known about breastfeeding. [1]
  • LiverTox likelihood score E (unlikely cause of clinically apparent liver injury). [2]
Interactions

Interactions

Ginkgo
From the table below 2 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Ginkgo
WithWhat happens
Anticoagulants such as warfarinGinkgo may increase the risk of bleeding. [1]
Antiplatelet drugsSeveral cases of excessive bleeding during ginkgo use have been attributed to interactions with antiplatelet drugs or anticoagulants. [2]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • Most trials in the Cochrane review tested the same standardized leaf extract at different doses. [3]
Regulation

Regulatory status

  • US: herbal products for oral use are often marketed as dietary supplements, which, unlike drugs, are not approved by the FDA before sale; manufacturers are responsible for safety and labeling. [1]
  • EU: an EU herbal monograph covers well-established use of the dry leaf extract for age-related cognitive impairment and quality of life in mild dementia, and traditional use of powdered leaf for minor circulation problems. [4]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Ginkgolides and bilobalide, which LiverTox notes are unique to this herb Terpenoids (terpene trilactones) [P7]
  • Flavonol glycosides, for which the USP-NF and British and European Pharmacopoeias stipulate a required range in ginkgo extract Flavonoids (flavonol glycosides) [P10]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 1 entry naming ginkgo (Ginkgo biloba), as one ingredient of a multi-ingredient tablet (listed as "Ginko Biloba") (NDI 497 submitted 2007-12-03). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P1]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • IARC Group 2B (possibly carcinogenic to humans): Ginkgo biloba extract, IARC Monographs Volume 108 (2016). [P2]
  • NTP TR-578 (March 2013), Ginkgo biloba extract by gavage for 2 years: some evidence of carcinogenic activity in male and female F344/N rats (thyroid follicular cell neoplasms) and clear evidence in male and female B6C3F1/N mice (hepatocellular carcinoma and hepatoblastoma; also hepatocellular adenoma in females). [P9]
  • The NTP test extract contained 31.2% flavonol glycosides, 15.4% terpene lactones and 10.45 ppm ginkgolic acid; results apply to that material. [P9]

Liver (NIH LiverTox)

  • LiverTox likelihood score E: unlikely cause of clinically apparent liver injury (chapter last updated March 14, 2018). [P7]

Interactions with medicines

  • Anticoagulants such as warfarin: NCCIH: ginkgo may increase the risk of bleeding in people taking anticoagulant drugs. [P6]
  • Antiplatelet drugs and anticoagulants: LiverTox: several instances of excessive bleeding during ginkgo therapy have been attributed to drug interactions. [P7]
  • Anticoagulant and antiplatelet treatment: EU monograph: in patients with increased bleeding tendency and concomitant anticoagulant and antiplatelet treatment, use only after consulting a doctor. [P12]
  • Drugs metabolized by cytochrome P450: LiverTox: ginkgo shows some inhibition of cytochrome P450 activity in vitro, but at doses used in humans it appears to have little effect on drug metabolism. [P7]
  • Midazolam: MSK: a study in healthy subjects suggests ginkgo may decrease midazolam serum concentrations. [P8]
  • P-glycoprotein substrates: In healthy volunteers, ginkgo inhibits P-glycoprotein and may interfere with drugs it transports. [P8]
  • Trazodone; efavirenz; drugs that lower the seizure threshold: Case reports: coma in a patient taking trazodone; possible reduced efavirenz effect; seizures with medicines that lower the seizure threshold. [P8]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • A review of 78 publications estimated that 56.7% of ginkgo leaf samples (n = 533) were adulterated and/or mislabeled, the highest rate of the five herbs examined. [P4]
  • Three of eight ginkgo leaf retail products bought in Australia and Denmark showed adulteration with flavonol aglycones and contained genistein, an isoflavone not found in ginkgo leaf; pharmacopoeial assays that quantify aglycones after hydrolysis cannot detect added free aglycones (Wohlmuth et al., 2014). [P10]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P3]
  • Flavonol glycoside assay with free flavonol aglycones measured before and after hydrolysis; screen for genistein — Adulteration of ginkgo extract with free flavonol aglycones and genistein has been found in retail products and is missed by the standard assay alone. [P10]

Supply and conservation

  • IUCN Red List: Endangered (EN), via GBIF species API, retrieved 2026-10-29 [P5]

Absorption in people

  • In 12 healthy volunteers given Ginkgo biloba extract (EGb 761) orally while fasting, absolute bioavailability was 0.80 for ginkgolide A, 0.88 for ginkgolide B and 0.79 for bilobalide; half-lives were 4.50, 10.57 and 3.21 h. Food did not change AUC but delayed Tmax. [P11]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • EU herbal monograph on Ginkgo biloba L., folium (EMA/HMPC/321097/2012, 28 January 2015): well-established use, adults and elderly, dry extract (DER 35–67:1, acetone 60% m/m) 120–240 mg per dose, 240 mg daily, for at least 8 weeks; traditional use, powdered leaf 250–360 mg per dose, 750 mg daily. [P12]

Pregnancy and breastfeeding

  • EU monograph: well-established use is contraindicated in pregnancy; ginkgo extracts may impair platelet aggregation and increase bleeding tendency, and use during lactation is not recommended. [P12]
  • NCCIH: ginkgo may be unsafe during pregnancy and might cause early labor or extra bleeding during delivery if used near that time; little is known about breastfeeding. [P6]

Sources for this profile

  1. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  2. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
  3. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  4. Orhan N, Gafner S, Blumenthal M. Estimating the extent of adulteration of the popular herbs black cohosh, echinacea, elder berry, ginkgo, and turmeric: its challenges and limitations. Nat Prod Rep 2024;41(10):1604-1621 (PMID 39108221), 2024-10-17. pubmed.ncbi.nlm.nih.gov
  5. GBIF species API: IUCN Red List category for Ginkgo biloba, 2026-10-29. api.gbif.org
  6. NCCIH. Ginkgo: Usefulness and Safety (Last Updated: February 2025), 2025-02. nccih.nih.gov
  7. NIH LiverTox (NIDDK). Ginkgo (Last Update: March 14, 2018), 2018-03-14. ncbi.nlm.nih.gov
  8. Memorial Sloan Kettering Cancer Center. About Herbs: Ginkgo (last updated August 9, 2023), 2023-08-09. mskcc.org
  9. National Toxicology Program. TR-578: Toxicology and Carcinogenesis Studies of Ginkgo Biloba Extract (CASRN 90045-36-6) in F344/N Rats and B6C3F1/N Mice (Gavage Studies), March 2013 (abstract), 2013-03. ntp.niehs.nih.gov
  10. Wohlmuth H, et al. Adulteration of Ginkgo biloba products and a simple method to improve its detection. Phytomedicine 2014;21(6):912-918 (PMID 24566389), 2014-05-15. pubmed.ncbi.nlm.nih.gov
  11. Fourtillan JB, et al. Pharmacokinetic properties of bilobalide and ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761). Therapie 1995;50(2):137-144 (in French; PMID 7631288), 1995-03. pubmed.ncbi.nlm.nih.gov
  12. European Medicines Agency, HMPC. European Union herbal monograph on Ginkgo biloba L., folium, EMA/HMPC/321097/2012 (Final, 28 January 2015), 2015-01-28. ema.europa.eu
Sources

Sources

  1. NCCIH. Ginkgo: Usefulness and Safety (Last Updated: 2025-02), 2025-02. nccih.nih.gov
  2. NIH LiverTox (NIDDK). Ginkgo (Last Update: 2018-03-14), 2018-03-14. ncbi.nlm.nih.gov
  3. Cochrane Database of Systematic Reviews. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. 2009;(1):CD003120 (PubMed abstract, PMID 19160216), 2009-01-21. pubmed.ncbi.nlm.nih.gov
  4. European Medicines Agency, HMPC. Ginkgo folium (ginkgo leaf) - herbal medicinal product, 2015-12-14. ema.europa.eu
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.